Compare FKWL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | GANX |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 76.8M |
| IPO Year | 1997 | 2021 |
| Metric | FKWL | GANX |
|---|---|---|
| Price | $2.43 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $7.50 |
| AVG Volume (30 Days) | 10.1K | ★ 328.2K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,086,901.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $2.21 | $1.53 |
| 52 Week High | $5.48 | $4.34 |
| Indicator | FKWL | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 48.30 |
| Support Level | $2.21 | $1.71 |
| Resistance Level | $2.48 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 40.00 | 38.83 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.